Key clinical point: Real-life study confirms the efficacy, safety, and high retention rate of secukinumab in patients with moderate-to-severe psoriatic arthritis (PsA), with male sex being an independent predictor of treatment response.
Major finding: The mean 28-Joint Disease Activity Score using C-reactive protein was significantly lower at week 52 vs baseline (2.2 vs 5.8; P = .0001), suggesting remission, with men vs women being more likely to achieve inactive disease or remission (odds ratio 5.16; 95% CI 1.35-26.63). The treatment retention rate at 1-year follow-up was 75%, with none of the patients discontinuing due to adverse events.
Study details: The data come from a retrospective study including 85 patients with moderate-to-severe PsA (n = 56) or ankylosing spondylitis (n = 29) treated with secukinumab and followed for 52 weeks.
Disclosures: This study did not receive any funding, except open access funding through Projekt DEAL, Germany. The authors declared no conflicts of interest.
Source: Molica Colella F et al. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: A 52-week real-life study in an Italian cohort. Adv Rheumatol. 2023;63(1):15 (Mar 27). Doi: 10.1186/s42358-023-00295-2